Prognostic value of metastatic sites in patients with mCRC treated with regorafenib

Cristina Smolenski, MD, Gustave Roussy, Villejuif, France, discusses the prognostic value of different metastatic sites in the Phase II PRODIGE 68 - UCGI 38 - SOREGATT trial (NCT04450836) of regorafenib and trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer (mCRC). Results indicated no significant differences in overall survival (OS) and progression-free survival (PFS) across metastatic site groups, though ECOG status was associated with better OS. Further studies are required for better patient selection. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.